Skip to main content

Lupus clinical trials at UCSF

3 in progress, 2 open to eligible people

Showing trials for
  • A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis

    open to eligible people ages 12-17

    This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics of obinutuzumab in adolescent participants aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).

    San Francisco, California and other locations

  • VIBRANT: VIB4920 for Active Lupus Nephritis

    open to eligible people ages 18 years and up

    This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

    San Francisco, California and other locations

  • Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

    Sorry, in progress, not accepting new patients

    SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.

    San Francisco, California and other locations

Our lead scientists for Lupus research studies include .

Last updated: